Pharmaceuticals

Cusick's Corner The key today is do no damage. It's been an incredible month and the market is very quiet, so try not to over analyze the data and headlines today. Also don't interpret any market pullbacks (most likely due to some tax selling) as the beginning of the end or the time to really...

Shares of XOMA Ltd. (Nasdaq: XOMA) are trading up 8.6% at $5.54 per share during the Thursday afternoon trading session. The day's range for shares of XOMA Ltd has been between $5.10 and $5.84 per share. The average price target of analysts who cover XOMA Ltd. (XOMA) is $8.18 per share. Volume of 8...

Here is a quick peek at stocks that have abnormally high daily put/call ratios today relative to their average…. 1. Citrix Systems (NASDAQ: CTXS) 3,024 puts, 94 calls 2. NetApp (NASDAQ: NTAP) 9,952 puts, 418 calls 3. Barclays Bank (NYSE: BCS) 3,689 puts, 167 calls 4. Novartis AG (NYSE: NVS) 5,593...

Endo Pharmaceuticals' (ENDP) portfolio received a boost with the US Food and Drug Administration (FDA) clearing Fortesta Gel for treating men (above 18 years of age) with low levels of testosterone (low T or hypogonadism). The disease results from the failure of the body to produce normal amounts...

• BHP Billiton (NYSE:BHP) plans to offer a price of $90 per share for Anadarko (NYSE:APC) • Lockheed Martin (NYSE:LMT) was awarded a Navy contract yesterday to build 10 warships  known as Littoral Combat Ships, between now and 2015 worth up to $3.6 billion • Susquehanna increased its target price...

• BHP Billiton (NYSE:BHP) plans to offer a price of $90 per share for Anadarko (NYSE:APC) • Lockheed Martin (NYSE:LMT) was awarded a Navy contract yesterday to build 10 warships  known as Littoral Combat Ships, between now and 2015 worth up to $3.6 billion • Susquehanna increased its target price...

Even though the markets trimmed the intra-day rally during closing hours on Wednesday, the benchmarks still moved modestly upward to achieve new highs. After-effects of the snowstorm in the Northeast continued to keep investors away from the Street. In addition, the ongoing holiday season has...

Endo Pharmaceuticals' (ENDP) portfolio received a boost with the US Food and Drug Administration (FDA) clearing Fortesta Gel for treating men (above 18 years of age) with low levels of testosterone (low T or hypogonadism). The disease results from the failure of the body to produce normal amounts...

Even though the markets trimmed the intra-day rally during closing hours on Wednesday, the benchmarks still moved modestly upward to achieve new highs. After-effects of the snowstorm in the Northeast continued to keep investors away from the Street. In addition, the ongoing holiday season has...

Endo Pharmaceuticals Holdings (NASDAQ: ENDP) announced the FDA approval of Fortesta Gel, the company's topical treatment for low testosterone, Goldman Sachs reports. The company expects to launch the product early in 2011. “Fortesta enters a large and growing market, but we maintain our sales...

Endo Pharmaceuticals (NASDAQ: ENDP) is higher in pre-market trading by 4.8% to $36.94 after the company received FDA approval for FORTESTA. FORTESTA is a gel for men used to treat low levels of testosterone. The FDA approved it after satisfying concerns that it would rub off on children and women...

Piper Jaffray has a Neutral rating and a $39 price target on shares of Endo Pharmaceuticals (NASDAQ: ENDP). In a note sent to clients, Piper Jaffray writes, "Yesterday, Endo announced that the FDA approved Fortesta, a 2% gel formulation of testosterone for the treatment of male hypogonadism....